Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
Go back to Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial| Pfizer Inc. (NYSE: PFE) | Delayed: 25.08 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.08 | 52 Week High | $37.39 | |||
| Open | $25.08 | 52 Week Low | $28.25 | |||
| Day High | $25.08 | P/E | 15.20 | |||
| Day Low | $25.08 | EPS | $1.65 | |||
| Volume | 265,200 | |||||
| (NASDAQ: VALN) | Delayed: 5.35 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.35 | 52 Week High | $ | |||
| Open | $5.35 | 52 Week Low | $ | |||
| Day High | $5.35 | P/E | N/A | |||
| Day Low | $5.35 | EPS | $ | |||
| Volume | 1 | |||||
